Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement

NCT ID: NCT01664559

Last Updated: 2015-12-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 67 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2014-03-31

Brief Summary

Intrauterine device (IUD) placement can be painful for patients during and after the procedure. Fear of pain from IUD insertion can be a barrier to obtaining this highly effective long acting reversible contraception. Currently there are no proven effective methods for reduction of pain during and after placement of modern IUDs (Mirena IUD and Paragard IUD). Ketorolac has not been studied in regards to decreasing pain during and after IUD insertion although it is used by some providers for this purpose. It is a strong NSAID that is indicated for the treatment of moderate acute pain. In the intramuscular form it has an analgesia onset of action at 30min, thus may be a plausible option for pain management in the office setting compared to oral NSAIDs, which have a longer time to onset of analgesia and have not been proven to be effective in reducing pain associated with IUD placement. The primary aim of this study is to determine whether ketorolac (Toradol) decreases pain associated with intrauterine device placement compared to placebo. We hypothesize that administration of ketorolac 30mg intramuscularly at least 30 minutes prior to IUD insertion will decrease pain scores by at least 20mm on a visual analog scale at various time points during IUD insertion when compared to placebo of normal saline injection.

Detailed Description

Modern intrauterine devices are highly effective long acting reversible forms of contraception. The Mirena IUD is 99.8% effective and the Paragard copper IUD is 99.2% effective in preventing pregnancy (Zieman 2010). Fear of intrauterine device placement can be a barrier to obtaining this highly effective form of birth control. The current standard of care for pain management during and after IUD placement is no medication, as randomized control trials published to date have limited data regarding use of medications to decrease pain. There has been one trial to suggest that the use of naproxen with 1% lidocaine paracervical block compared to paracervical block alone may decrease pain after IUD placement in primarily nulliparous patients. However, this study was with the much wider and no longer available Dalkon Shield IUD. In addition, this study did not show any significant decrease in pain scores during IUD placement (Massey 1974). Studies to evaluate effectiveness of motrin and misoprostol have shown no significant decrease in pain scores during and after IUD insertion, although the majority of participants in these studies were multiparous (Jensen 1998, Hubacher 2006, Saav 1997). There is some suggestion that 2% lidocaine gel one minute prior to IUD insertion may have some decrease in pain, although this study was poorly designed (Oloto 1996).

There have been no studies published to date regarding the use of ketorolac for decreasing pain during and after IUD placement. Ketorolac is an acetic acid NSAID that reversibly inhibits COX 1 and 2, leading to decreased formation of prostaglandin precursors, and is indicated for the use of moderate acute pain in the short term setting. Its administration in the office setting may be good option for providers since intramuscular administration leads to analgesia beginning at 30 minutes, maximal effect 1 to 2 hours after administration, and duration of analgesia approximately 4 to 6 hours for the 30mg intramuscular injection.

Although there is no standard of care in regards to pain medication administration prior to IUD placement, providers at UCSD often suggest certain options. These include ibuprofen at least one hour prior to the procedure, or ibuprofen taken within a few hours after the procedure, or ketorolac injection at least 15-30 minutes prior to the procedure. It would be beneficial for providers to have an evidence based option for patients.

Conditions

Pain Control With IUD Insertion

Keywords

intrauterine device; ketorolac; toradol; mirena; paragard; pain control

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo with 1cc normal saline IM

If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.

Group Type: PLACEBO_COMPARATOR

Normal Saline

Intervention Type: DRUG

Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection

Toradol, 30mg in 1cc IM

If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.

Group Type: EXPERIMENTAL

Ketorolac

Intervention Type: DRUG

Ketorolac 30mg intramuscular injection, 1cc volume

Interventions

Ketorolac

Ketorolac 30mg intramuscular injection, 1cc volume

Intervention Type: DRUG

Normal Saline

Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection

Intervention Type: DRUG

Other Intervention Names

Brand name: toradol; Serial # (01) 1 030409 379649 7; REF# 196604

Eligibility Criteria

Inclusion Criteria

• Nulliparous and multiparous women ages 18-50, who are English or Spanish speaking, who present for intrauterine device placement for contraception or menorrhagia (in the case of Mirena IUD insertion).

Exclusion Criteria

• Pregnancy
• Any diagnosed chronic pain issues (i.e. fibromyalgia, endometriosis, dysmenorrhea, irritable bowel syndrome, interstitial cystitis)
• If the patient has taken any pain medications within 6 hours of enrollment, including aspirin or other NSAIDs
• Misoprostol administration within 24 hours of enrollment
• History of prior IUD insertion
• Known allergy to NSAIDs including diagnosis of aspirin or NSAID induced asthma or urticaria
• Known contraindications to NSAIDs, such as the following medications that are risk category D (consider therapy modification) or X (avoid combination) including

• bile acid sequestrants (D - may decrease absorption of NSAIDs)
• cyclosporine (D - NSAIDs may enhance the nephrotoxic effects)
• drotrecogin alfa (D - NSAIDs may enhance the adverse/toxic effects, cause bleeding)
• floctafenine (X - may enhance adverse/toxic effect of NSAIDs)
• lithium (D - NSAIDs may decrease serum concentration)
• methotrexate (D - NSAIDs may decrease excretion)
• pentoxifylline (X - Ketorolac may enhance adverse/toxic effects)
• probenecid (X - may increase serum concentration of Ketorolac)
• rivaroxaban (D - Anti-platelet drugs may enhance anti-coagulation effect)
• SSRIs (D - may enhance the anti-platelet effect of NSAIDs, NSAIDs may diminish the therapeutic effect of SSRIs)
• warfarin (D - NSAIDs may enhance the anti-coagulation effect)
• Renal insufficiency (by history and/or chart review)
• Peptic ulcer disease or history of significant gastrointestinal bleeding
• Known thrombocytopenia, known coagulopathy, or known bleeding disorder
• Known contraindications to IUD

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Lynn Ngo

OTHER

Sponsor Role: lead

Responsible Party

Lynn Ngo

Resident Physician

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Lynn L Ngo, MD

Role: STUDY_DIRECTOR

University of California, San Diego

Sheila Mody, MD MPH

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

University of California San Diego

San Diego, California, United States

Countries

United States

References

Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007373. doi: 10.1002/14651858.CD007373.pub2.

Reference Type: BACKGROUND

PMID: 19588429 (View on PubMed)

Roche NE, Li D, James D, Fechner A, Tilak V. The effect of perioperative ketorolac on pain control in pregnancy termination. Contraception. 2012 Mar;85(3):299-303. doi: 10.1016/j.contraception.2011.10.001. Epub 2011 Nov 30.

Reference Type: BACKGROUND

PMID: 22133656 (View on PubMed)

Edelman AB, Schaefer E, Olson A, Van Houten L, Bednarek P, Leclair C, Jensen JT. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception. 2011 Sep;84(3):234-9. doi: 10.1016/j.contraception.2011.01.016. Epub 2011 Mar 3.

Reference Type: BACKGROUND

PMID: 21843686 (View on PubMed)

Ngo LL, Ward KK, Mody SK. Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial. Obstet Gynecol. 2015 Jul;126(1):29-36. doi: 10.1097/AOG.0000000000000912.

Reference Type: DERIVED

PMID: 26241253 (View on PubMed)

Other Identifiers

WRHR 5K12001259-12 - toradol

Identifier Type: -

Identifier Source: org_study_id